Efficacy and Safety of Thirty-Day Dual-Antiplatelet Therapy Following Complex Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

Figures

• 

  Figure 1. Forest plot demonstrating the effect of very short-term versus more than 3 months dual antiplatelet treatment on net adverse clinical events, with odds ratio and 95% confidence intervals. Each square represents a study; the size of square is representative of the weight of each study. The diamond shows the result when all the particular studies are combined together and averaged. CI, confidence interval; DAPT, dual antiplatelet therapy; M-H, Mantel–Haenszel.

• 

  Figure 2. Forest plot demonstrating the effect of very short-term versus more than 3-month dual antiplatelet treatment on major adverse clinical events, with odds ratio and 95% confidence intervals. CI, confidence interval; DAPT, dual antiplatelet therapy; M-H, Mantelel Haenszel; MACE, major adverse cardiovascular events.

• 

  Figure 3. Forest plot demonstrating the effect of very short-term versus more than 3-month dual antiplatelet treatment on all-cause mortality, with odds ratio and 95% confidence intervals. CI, confidence interval; DAPT, dual antiplatelet therapy; M-H, Mantelel Haenszel.

• 

  Figure 4. Forest plot demonstrating the effect of very short-term versus more than 3-month dual antiplatelet treatment on myocardial infarction (A) and stroke (B), with odds ratio and 95% confidence intervals. CI, confidence interval; DAPT, dual antiplatelet therapy; M-H, Mantelel Haenszel.

• 

  Figure 5. Forest plot demonstrating the effect of very short-term versus more than 3-month dual antiplatelet treatment on stent thrombosis, with odds ratio and 95% confidence intervals. CI, confidence interval; DAPT, dual antiplatelet therapy; M-H, Mantelel–Haenszel.

• 

  Figure 6. Forest plot demonstrating the effect of very short-term versus more than 3-month dual antiplatelet treatment on major bleedings, with odds ratio and 95% confidence intervals. CI, confidence interval; DAPT, dual antiplatelet therapy; M-H, Mantelel–Haenszel.